Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
With the aim of introducing health coverage for fertility treatments from next April, the Ministry of Health, Labor and Welfare (MHLW) presented a proposal to a key reimbursement policy panel on December 15, saying that “drugs that have received regulatory…
To read the full story
Related Article
- 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
- Chuikyo Calls for Smooth Transition to Fertility Treatment Coverage from Current Subsidy System
November 18, 2021
- Japan to Discuss Approval of Individual Fertility Drugs after August
July 26, 2021
- Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
June 25, 2021
- Chuikyo Receives Report on Fertility Treatment Survey, Awaits Guidelines to Discuss Coverage
April 16, 2021
REGULATORY
- MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable
January 8, 2025
- PMDA Reviewing Safety Risks for Joyclu, Lixiana, Keytruda
January 7, 2025
- MHLW’s FY2025 Budget Includes 7.7 Billion Yen to Drive Drug Commercialization
January 6, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…